This study aims to elucidate the specific mechanism by which ALKBH5 mediates m6A modification through the TUG1/SH3BGRL pathway, contributing to ADR resistance in AML cells, thereby providing a new theoretical foundation for improving AML treatment. Here, ALKBH5 is linked to acute myeloid leukemia.